

ARO A BIOSURGERY INVESTOR DAY

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'Aroa' or the 'Company') is pleased to announce it will hold an Investor Day for shareholders and interested parties at 10am-1pm NZT (8am-11am AEST) Monday 5 July 2021.

The event will be conducted both in-person at the Company's Auckland headquarters as well as virtually. All attendees are required to register in advance of the event. The Company will take questions following each session.

Virtual attendance

Register for the Investor Day at: <https://myevents.nz/aroa/investorsday/live.bsp>

In-person attendance

Register by contacting Lorraine Shepherd at Lorraine.Shepherd@aroabio.com

Address: 64 Richard Pearse Drive, Auckland, New Zealand

Agenda (all times NZT)

Introduction 10.00 – 10.10am

Brian Ward (Chief Executive Officer)

ARO A ECM™ Product Portfolio 10.10 – 10.40am

Dr Frazer Murray (Director of Global Marketing & Strategy)

US Sales 10.40 – 11.10am

Brad Adams (VP Commercial), Wes Snodgrass (Director National Accounts), Brian Ward (Chief Executive Officer)

Clinical Evidence 11.10 – 11.40am

Dr Brandon Bosque (Medical Science Liaison), Dr Barnaby May (Chief Scientific Officer)

Session Break 11.40 – 11.50am

Dead Space Management Platform 11.50am – 12.20pm

Shane Dowling (Medical Science Liaison), Isaac Mason (Director of Product Development)

Manufacturing Overview 12.20 – 12.50pm

Simone Von Fircks (Chief Operations Officer), Rod Stanley (Director Manufacturing)

FY2022 Outlook & Executive Q&A 12.50 – 1.00pm

Brian Ward (Chief Executive Officer), Brad Adams (VP Commercial), Dr Barnaby May (Chief Scientific Officer), Simone Von Fircks (Chief Operations Officer), James Agnew (Chief Financial Officer)

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.



About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Clinically proven with peer reviewed publications, AROA's products have been used in more than four million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX).

www.aroabio.com/

Contacts

Investor

Simon Hinsley

Investor Relations

shinsley@aroabio.com

+ 61 401 809 653

Media

Australia

Matthew Wright

matt@nwrcommunications.com.au

+61 451 896 420

New Zealand

Piet De Jong

piet.dejong@baldwinboyle.com

+64 21 812 766